日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Immune Checkpoint Inhibitor-induced Mass-forming Pancreatitis and Lipodystrophy: A Case Report and Review of the Literature

免疫检查点抑制剂诱发的肿块型胰腺炎和脂肪营养不良：病例报告及文献综述

期刊:Internal Medicine
影响因子:1.1
doi:10.2169/internalmedicine.5072-24
Oi, Yuka; Takayanagi, Takuya; Kakuta, Koki; Arioka, Hitoshi; Matsunaga, Tatsuya
胰腺炎
Checkpoint
免疫/内分泌
发表日期：2025
文献求助 收藏

Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)

在第 2-4 天使用帕洛诺司琼、神经激肽-1 受体拮抗剂和奥氮平联合顺铂治疗以减少地塞米松用量：一项随机 III 期试验（SPARED 试验）

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-023-02493-7
Minatogawa, Hiroko; Izawa, Naoki; Shimomura, Kazuhiro; Arioka, Hitoshi; Iihara, Hirotoshi; Sugawara, Mitsuhiro; Morita, Hajime; Mochizuki, Ayako; Nawata, Shuichi; Mishima, Keisuke; Tsuboya, Ayako; Miyaji, Tempei; Honda, Kazunori; Yokomizo, Ayako; Hashimoto, Naoya; Yanagihara, Takeshi; Endo, Junki; Kawaguchi, Takashi; Furuya, Naoki; Sone, Yumiko; Inada, Yusuke; Ohno, Yasushi; Katada, Chikatoshi; Hida, Naoya; Akiyama, Kana; Ichikura, Daisuke; Konomatsu, Akiko; Ogura, Takashi; Yamaguchi, Takuhiro; Nakajima, Takako Eguchi
信号转导
RED
发表日期：2024
文献求助 收藏

Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator

针对癌症疼痛患者的双层缓释曲马多片剂的III期研究：一项双盲平行组、非劣效性研究，以速释曲马多胶囊作为活性对照

期刊:Supportive Care in Cancer
影响因子:3
doi:10.1007/s00520-023-08242-z
Shinkai, Masaharu; Katsumata, Noriyuki; Kawai, Shinichi; Kuyama, Shoichi; Sasaki, Osamu; Yanagita, Yasuhiro; Yoshida, Minoru; Uneda, Shima; Tsuji, Yasushi; Harada, Hidenori; Nishida, Yasunori; Sakamoto, Yasuhiro; Himeji, Daisuke; Arioka, Hitoshi; Sato, Kazuhiro; Katsuki, Ryo; Shomura, Hiroki; Nakano, Hideshi; Ohtani, Hideaki; Sasaki, Kazutaka; Adachi, Takeshi
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

更正：日本乳腺癌学会乳腺癌系统治疗临床实践指南（2018版）

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-021-01252-x
Shimoi, Tatsunori; Nagai, Shigenori E; Yoshinami, Tetsuhiro; Takahashi, Masato; Arioka, Hitoshi; Ishihara, Mikiya; Kikawa, Yuichiro; Koizumi, Kei; Kondo, Naoto; Sagara, Yasuaki; Takada, Masahiro; Takano, Toshimi; Tsurutani, Junji; Naito, Yoichi; Nakamura, Rikiya; Hattori, Masaya; Hara, Fimikata; Hayashi, Naoki; Mizuno, Toshiro; Miyashita, Minoru; Yamashita, Nami; Yamanaka, Takashi; Saji, Shigehira; Iwata, Hiroji; Toyama, Tatsuya
肿瘤
肿瘤免疫
乳腺癌
发表日期：2021
文献求助 收藏

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

日本乳腺癌学会乳腺癌系统治疗临床实践指南（2018版）

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-020-01085-0
Shimoi, Tatsunori; Nagai, Shigenori E; Yoshinami, Tetsuhiro; Takahashi, Masato; Arioka, Hitoshi; Ishihara, Mikiya; Kikawa, Yuichiro; Koizumi, Kei; Kondo, Naoto; Sagara, Yasuaki; Takada, Masahiro; Takano, Toshimi; Tsurutani, Junji; Naito, Yoichi; Nakamura, Rikiya; Hattori, Masaya; Hara, Fimikata; Hayashi, Naoki; Mizuno, Toshiro; Miyashita, Minoru; Yamashita, Nami; Yamanaka, Takashi; Saji, Shigehira; Iwata, Hiroji; Toyama, Tatsuya
肿瘤
肿瘤免疫
乳腺癌
发表日期：2020
文献求助 收藏

Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy

SPARED试验研究方案：一项随机、非劣效性III期临床试验，比较接受顺铂化疗的患者在第1天单独使用地塞米松与在第1-4天联合使用地塞米松、神经激肽-1受体拮抗剂帕洛诺司琼和奥氮平（5 mg）的疗效。

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2020-041737
Minatogawa, Hiroko; Izawa, Naoki; Kawaguchi, Takashi; Miyaji, Tempei; Shimomura, Kazuhiro; Kazunori, Honda; Iihara, Hirotoshi; Ohno, Yasushi; Inada, Yusuke; Arioka, Hitoshi; Morita, Hajime; Hida, Naoya; Sugawara, Mitsuhiro; Katada, Chikatoshi; Nawata, Shuichi; Ishida, Hiroo; Tsuboya, Ayako; Tsuda, Takashi; Yamaguchi, Takuhiro; Nakajima, Takako Eguchi
信号转导
RED
发表日期：2020
文献求助 收藏

Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer

一项随机II期研究评估了nab-紫杉醇作为HER2阴性转移性乳腺癌患者一线化疗的疗效

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.13221
Tamura, Kenji; Inoue, Kenichi; Masuda, Norikazu; Takao, Shintaro; Kashiwaba, Masahiro; Tokuda, Yutaka; Iwata, Hiroji; Yamamoto, Naohito; Aogi, Kenjiro; Saeki, Toshiaki; Nakayama, Takahiro; Sato, Nobuaki; Toyama, Tatsuya; Ishida, Takanori; Arioka, Hitoshi; Saito, Mitsue; Ohno, Shinji; Yamauchi, Hideko; Yamada, Kimito; Watanabe, Junichiro; Ishiguro, Hiroshi; Fujiwara, Yasuhiro
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2017
文献求助 收藏

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.

针对晚期肝细胞癌患者，开展 TSU-68（一种口服抗血管生成药物）与 S-1 联合用药的安全性、药代动力学特征和疗效的 I 期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-014-0109-2
Ikeda Masafumi, Shiina Shuichiro, Nakachi Kohei, Mitsunaga Shuichi, Shimizu Satoshi, Kojima Yasushi, Ueno Hideki, Morizane Chigusa, Kondo Shunsuke, Sakamoto Yasunari, Asaoka Yoshinari, Tateishi Ryosuke, Koike Kazuhiko, Arioka Hitoshi, Okusaka Takuji
细胞生物学
血管生成
发表日期：2014
文献求助 收藏

Serum p53 antibody in breast cancer

乳腺癌血清p53抗体

期刊:Cancer Biomarkers
影响因子:1.9
doi:10.3233/CBM-140396
Yamamoto, Shinya; Chishima, Takashi; Adachi, Shouko; Harada, Fumi; Toda, Youko; Arioka, Hitoshi; Hasegawa, Naoki; Kakuta, Yukio
肿瘤
肿瘤免疫
乳腺癌
发表日期：2014
文献求助 收藏

Breast cancer manifested by hematologic disorders

乳腺癌表现为血液系统疾病

期刊:Journal of Thoracic Disease
影响因子:1.9
doi:10.3978/j.issn.2072-1439.2012.10.17
Ishikawa, Takashi; Shimizu, Daisuke; Kito, Ayako; Ota, Ikuko; Sasaki, Takeshi; Tanabe, Mikiko; Yamada, Akimitsu; Arioka, Hitoshi; Shimizu, Satoru; Wakasugi, Junichi; Mori, Ryutaro; Chishima, Takashi; Ichikawa, Yasushi; Endo, Itaru
肿瘤
肿瘤免疫
乳腺癌
发表日期：2012
文献求助 收藏